Detailed Analysis of ITPR1 Missense Variants Guides Diagnostics and Therapeutic Design

Background The ITPR1 gene encodes the inositol 1,4,5‐trisphosphate (IP3) receptor type 1 (IP3R1), a critical player in cerebellar intracellular calcium signaling. Pathogenic missense variants in ITPR1 cause congenital spinocerebellar ataxia type 29 (SCA29), Gillespie syndrome (GLSP), and severe pont...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders Vol. 39; no. 1; pp. 141 - 151
Main Authors: Tolonen, Jussi Pekka, Parolin Schnekenberg, Ricardo, McGowan, Simon, Sims, David, McEntagart, Meriel, Elmslie, Frances, Shears, Debbie, Stewart, Helen, Tofaris, George K., Dabir, Tabib, Morrison, Patrick J., Johnson, Diana, Hadjivassiliou, Marios, Ellard, Sian, Shaw‐Smith, Charles, Znaczko, Anna, Dixit, Abhijit, Suri, Mohnish, Sarkar, Ajoy, Harrison, Rachel E., Jones, Gabriela, Houlden, Henry, Ceravolo, Giorgia, Jarvis, Joanna, Williams, Jonathan, Shanks, Morag E., Clouston, Penny, Rankin, Julia, Blumkin, Lubov, Lerman‐Sagie, Tally, Ponger, Penina, Raskin, Salmo, Granath, Katariina, Uusimaa, Johanna, Conti, Hector, McCann, Emma, Joss, Shelagh, Blakes, Alexander J.M., Metcalfe, Kay, Kingston, Helen, Bertoli, Marta, Kneen, Rachel, Lynch, Sally Ann, Martínez Albaladejo, Inmaculada, Moore, Austen Peter, Jones, Wendy D., Becker, Esther B.E., Németh, Andrea H.
Format: Journal Article
Language:English
Published: Hoboken, USA John Wiley & Sons, Inc 01-01-2024
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The ITPR1 gene encodes the inositol 1,4,5‐trisphosphate (IP3) receptor type 1 (IP3R1), a critical player in cerebellar intracellular calcium signaling. Pathogenic missense variants in ITPR1 cause congenital spinocerebellar ataxia type 29 (SCA29), Gillespie syndrome (GLSP), and severe pontine/cerebellar hypoplasia. The pathophysiological basis of the different phenotypes is poorly understood. Objectives We aimed to identify novel SCA29 and GLSP cases to define core phenotypes, describe the spectrum of missense variation across ITPR1, standardize the ITPR1 variant nomenclature, and investigate disease progression in relation to cerebellar atrophy. Methods Cases were identified using next‐generation sequencing through the Deciphering Developmental Disorders study, the 100,000 Genomes project, and clinical collaborations. ITPR1 alternative splicing in the human cerebellum was investigated by quantitative polymerase chain reaction. Results We report the largest, multinational case series of 46 patients with 28 unique ITPR1 missense variants. Variants clustered in functional domains of the protein, especially in the N‐terminal IP3‐binding domain, the carbonic anhydrase 8 (CA8)‐binding region, and the C‐terminal transmembrane channel domain. Variants outside these domains were of questionable clinical significance. Standardized transcript annotation, based on our ITPR1 transcript expression data, greatly facilitated analysis. Genotype–phenotype associations were highly variable. Importantly, while cerebellar atrophy was common, cerebellar volume loss did not correlate with symptom progression. Conclusions This dataset represents the largest cohort of patients with ITPR1 missense variants, expanding the clinical spectrum of SCA29 and GLSP. Standardized transcript annotation is essential for future reporting. Our findings will aid in diagnostic interpretation in the clinic and guide selection of variants for preclinical studies. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Bibliography:Funding agency
Relevant conflicts of interest/financial disclosures
Esther B. E. Becker and Andrea H. Németh share senior authorship.
The authors declare that no competing interests exist.
This work was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska‐Curie grant agreement No 101023312, Nuffield Department of Clinical Neurosciences (University of Oxford), Ataxia UK, Action Medical Research (GN2063), the Wellcome Trust (161/037, 223521/Z/21/Z), Henry Smith Charity, the John Fell Oxford University Press Research Fund, the Medical Research Council (MR/V007068/1), Orionin Tutkimussäätiö, Sigrid Juséliuksen Säätiö, Stiftelsen Alma och K. A. Snellman Säätiö, Lastentautien Tutkimussäätiö, and the Research Council of Finland (356676, 331436).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Relevant conflicts of interest/financial disclosures: The authors declare that no competing interests exist.
Funding agency: This work was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska‐Curie grant agreement No 101023312, Nuffield Department of Clinical Neurosciences (University of Oxford), Ataxia UK, Action Medical Research (GN2063), the Wellcome Trust (161/037, 223521/Z/21/Z), Henry Smith Charity, the John Fell Oxford University Press Research Fund, the Medical Research Council (MR/V007068/1), Orionin Tutkimussäätiö, Sigrid Juséliuksen Säätiö, Stiftelsen Alma och K. A. Snellman Säätiö, Lastentautien Tutkimussäätiö, and the Research Council of Finland (356676, 331436).
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.29651